iRadimed Corporation (IRMD) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, iRadimed Corporation (NASDAQ: IRMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $85.74 (+2.16% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #110 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C+ (68/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 20.5% FCF Margin ($17.2M FCF) & 76.7% Gross Margin
FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 25.6 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)
Even with a 68/100 (C+) score, IRMD faces multiple-compression risk if 48.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 74.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($85.66) or 200D SMA ($92.54) invalidates the momentum regime and cuts Target Base ($89.60) toward Bear Floor ($69.89).
iRadimed Corporation (IRMD) surged +2.16% to $85.74, trading at 30% of its 52-week range ($76.35 – $107.9). Solid 77% profit margin (38% return on capital), mixed timing at 49x P/E—hold if owned, no rush to chase.
IRADIMED has pulled back in the short term after a strong multi year run. This puts the spotlight squarely on whether the current share price is properly anchored to the cash it can generate. With the analysis lens fixed
Moby summary of IRadimed Corporation's Q3 2026 earnings call
New pump model drives record revenue and bookings as production ramps.
iRadimed (NASDAQ:IRMD) reported record third-quarter revenue as shipments of its newly launched 3870 MR IV pump accelerated, while the company said it is moderating its production ramp to protect product quality. Revenue
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call October 30, 2026 11:00 AM EDTCompany ParticipantsRoger Susi - Founder, Chairman, CEO & PresidentJohn...
(IRMD) on Friday reported profit of $6.The Orlando, Florida-based company said it had net income of 51 cents per share.
Announces Regular Quarterly Cash Dividend of $0.20 Per ShareReports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.
iRadimed (NASDAQ:IRMD) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.55 per share which met the analyst consensus estimate. This is a 17.02 percent increase over earnings of $0.47 per share from the same period last year. The
iRadimed (NASDAQ:IRMD) narrows FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$1.94 vs $1.94 analyst estimate..
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, iRadimed Corporation (IRMD) ranks #110 by composite RQD confidence (68/100, grade C+) and #351 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRMD
ACTIVE
iRadimed Corporation | C+ | 68/100 | 48.8x | 76.7% | 37.7% | +2.16% | $1.10B | Benchmark Subject |
| SGP SpyGlass Pharma Inc. | D- | 41/100 | — | — | -35.0% | -1.06% | $1.09B | /sgp-vs-irmd → |
| AORT Artivion Inc. | D+ | 54/100 | 117.0x | 64.4% | 4.5% | +2.27% | $1.14B | /aort-vs-irmd → |
| PRCT PROCEPT BioRobotics Corporation | D | 48/100 | — | 63.7% | -35.0% | +0.50% | $1.16B | /prct-vs-irmd → |
| SIBN SI-BONE Inc. | D | 48/100 | — | 79.6% | -10.3% | +2.66% | $1.00B | /sibn-vs-irmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), iRadimed Corporation (IRMD) reported GAAP revenue of $83.8M (+14.4% vs. FY2024 revenue of $73.2M , and +27.8% cumulative change since FY2023) , GAAP net income of $22.5M, operating cash flow of $24.9M, and free cash flow of $17.2M (-2.5% YoY). On the balance sheet, IRMD closed FY2025 with $108.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $83.8M | $22.5M | $24.9M | $17.2M | $108.8M | — |
| FY2024 (FY) | 2024-12-31 | $73.2M | $19.2M | $25.6M | $17.6M | $98.3M | — |
| FY2023 (FY) | 2023-12-31 | $65.6M | $17.2M | $13.5M | $13.5M | — | — |
As of 2026-11-01, iRadimed Corporation (NASDAQ: IRMD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $85.74 (+2.16% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IRMD ranks #110 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), IRMD carries a Roarable C+ (68/100 RQD), trailing P/E of 48.8x, gross margin of 76.7%, and ROIC of 37.7%. By comparison, SGP (SpyGlass Pharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $1.09B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per IRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001325618), iRadimed Corporation generated $83.8M in revenue (+14.4% YoY), $22.5M in net income, and $17.2M in free cash flow against $108.8M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (77% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 49x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
IRMD last traded at $85.74 (+2.16% on volume of 92,640 shares), positioning the stock +0.09% above its 50-day simple moving average ($85.66) and -7.35% below its 200-day simple moving average ($92.54). Across its 52-week range of $76.35 to $107.90, IRMD sits at the 29.8% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±5.6% ($80.94 to $90.54).
Why IRMD Stock surged +2.16% Today — RQD Quant Desk Flash. Solid 77% profit margin (38% return on capital), mixed timing at 49x P/E—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.